Fostering efficacy of anti &NDASH; PD-1 &NDASH; treatment: Nivolumab plus radiotherapy in advanced NSCLC

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms FORCE

12 Jan 2021 Status changed from active, no longer recruiting to completed.
21 Sep 2020 Primary endpoint (ORR according to RECIST 1.1 criteria) has not been met, according to results presented at the 45th European Society for Medical Oncology Congress
21 Sep 2020 Results from preliminary analysis assessing objective response rate and adverse events presented at the 45th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com